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Abstract
Background: Adherence is the key to the effectiveness of antiretroviral therapy. However, many factors have been identified as facilitating or hamper-
ing adherence. The aim of this study was to determine barriers and facilitators of adherence with particular emphasis on adverse effects.
Methods: A survey of patients, who started antiretroviral treatment between July 2004 and August 2005, was conducted by means of a semi-struc-
tured questionnaire. Those who consented to participate were interviewed for the collection of information on sociodemographic characteristics and 
clinical and other data. 
Results: The 180 patients who participated had a mean age of 36.7 (±8.1); 68.8% were female, 86.7% unemployed, 73.9% had a high school level 
of education, and 77.8% were single. Some 8.9% of the respondents used at least one non-prescribed medicine, while 34.4% received disability 
grants. Overall, 94% of the respondents reported at least one side effect; the mean number of self-reported side effects was 2.6 (± 1.4). With regard 
to adherence, the mean number of doses missed during the last seven days prior to the interview was 2.7 (±3.9), ranging from 0 to 18. The mean 
adherence level was 92.3%, ranging from 48.6% to 100.0%; overall, only 57.2% reported taking at least or over 95% of their prescribed doses. The 
two most common reasons for missing doses were forgetting (26.6%) followed by being away from home (15.6%). In the bivariate analysis, the only 
facilitator or factor that was significantly associated with at least or over 95% self-reported adherence was eating well (80.6% vs 64.5%; p = 0.025), 
whereas barriers or factors more likely and significantly associated with with self-reported adherence of at least or over 95%  included having used 
non-prescribed medicines (15.6% vs 3.9%; p = 0.008), having suffered from headaches (28.6 vs 14.6%; p = 0.026) and reported symptoms such 
as insomnia (27.3% vs 12.6%; p = 0.013) and abdominal pain (20.8% vs 9.7%; p = 0.037). In the multivariate analysis, the facilitators or factors that 
were significantly associated with self-reported adherence of at least or over 95% were having an initial bodyweight of less than 50 kg (p = 0.026) 
and viral load of >33 000 copies /ml (p = 0.047). 
Conclusions: In conclusion, self-reported barriers to optimal adherence included the use of non-prescribed drugs, and the presence of side effects 
such as insomnia, headaches and abdominal pain; while eating well was a facilitator. These findings emphasise the need for better communication 
between patients and clinicians, and the need for integrating pharmacovigilance concepts in clinical practice. 
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Introduction
Conceptually, complete adherence implies that a patient takes 100% of 
all doses of each prescribed medicine according to instructions he or 
she received from the prescribing doctor and/or dispensing pharmacist. 
The instructions refer to the taking of medicines in terms of the 
frequency and interval between doses, the need to take the medicines 
with or without foods, as well as other precautions.1 Adherence is the 
key to the effectiveness of the antiretroviral therapy because, in order 
to ensure that the viral load in a patient is kept at undetectable levels, 
high levels of adherence (about 100%) are required.2 However, in the 
case of antiretroviral therapy (ART), it is estimated that the average 
rate of adherence is approximately 70%, well in the same order as with 
other chronic conditions.3 Studies from Canada, Latin America and 
elsewhere demonstrate similar rates of suboptimal adherence.4,5 In 
general, 10% of patients report missing at least one antiretroviral dose 
on any given day and 33% report missing at least one dose within the 
past month.6 In South Africa, in a 48-week study involving 289 patients 
attending a public hospital, HIV clinic and receiving ART through 
Phase III studies, the mean adherence as measured by clinic-based 
pill counts and pharmacy refill data was 87.2%.7 Although many factors 
have been identified as being associated with less optimal adherence, 
the types of adverse effects involved with such level of adherence is 
still less established in South Africa. The objectives of this study were 
to determine the level of self-reported adherence, the reasons given 
for missing doses, the adverse effects self-reported, and to assess the 
association between adverse effects and adherence. 
Methods
A survey was conducted of HIV-infected patients, who started ART 
between July 2004 and August 2005 at the Dr George Mukhari 
Hospital in Pretoria. The population of the study comprised patients 
treated at the antiretroviral treatment clinic within the hospital. 
Recruitment into the study was processed during a seven-week period 
from July to August 2005. The recruitment was conducted during the 
morning 8:30 to 12:00 and the afternoon sessions 13:00 to 16:00. 
All consecutive patients, both males and females, were approached 
and requested to be interviewed. Only patients who were actually on 
ART and who consented to participate in the study were immediately 
interviewed. Patients who were unable to respond to an interview 
were also excluded. Using a pre-tested semi-structured questionnaire, 
data was collected by two trained interviewers on sociodemographic 
characteristics, clinical data, experienced side effects and non-
prescribed medicines as reported elsewhere.8 In this study, adherence 
was assessed in terms of dose taking, the prescribed number of 
tablets to be taken for each day. Bivariate and multivariate analyses 
of relationships between self-reported adherence with explanatory 
variables were performed using logistic regression. The findings 
presented here are a component of a study that was approved by 
the Ethics Committee of the Faculty of Medicine at the University of 
Limpopo.
Results
From 285 patients who were approached, a response rate of 63.2% 
was achieved. The 180 patients who consented to be interviewed 
had a mean age of 36.7 (±8.1) years, ranging from 19 to 63 years 
(see Figure 1); 68.8% were female, 86.7% unemployed, 73.9% had 
a high school level of education, and 77.8% were single. Some 8.9% 
of respondents used at least one non-prescribed medicine, while 
34.4% received disability grants. Overall, 73.9% reported eating daily 
balanced diets including fruits and vegetables. The most prescribed 
regimen comprised stavudine, lamivudine and efavirenz  (Table I) 
Figure 1: Age characteristics of respondents
Table I: Regimens prescribed to respondents (n = 180)
Regimen 
prescribed Composition Frequency Percent
Regimen 1a Stavudine, lamivudine, efavirenz 169 93.8
Regimen 1b Stavudine, lamivudine, nevirapine 9 5
Regimen 2 Didanosine, lamivudine, efavirenz 1 0.6
Regimen 3 Zidovudine, lamivudine, efavirenz 1 0.6
With regard to self-reported adverse effects, overall 94% of 
respondents reported at least one side effect. Respondents reported 
19 different side effects (see Table II). The side effects or symptoms 
reported by at least 10% of respondents were, in descending order, 
sexual problems, depression, forgetfulness, muscle pains, insomnia, 
fever, suicide ideation, abdominal pain, nightmares and loss of 
appetite. The average number of side effects reported was 2.6 (±1.4).
Table II: Adverse effects self-reported (n = 180)
Adverse effects Frequency Percent
Sexual problems (decreased libido, 
satisfaction) 40.0
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With regard to adherence, overall only 57.2% reported taking ≥ 95% of 
their prescribed doses. The mean number of doses missed during the 
last seven days prior to the interview was 2.7 (±3.9), ranging from 0 to 
18. Although 50.6% reported not missing any dose, 8.9%, 35.6% and 
5% reported missing one to two doses, three to ten doses, and more 
than ten doses, respectively. The mean adherence was 92.3%, ranging 
from 48.6% to 100.0%; overall, only 57.2% reported taking 
≥ 95% of their prescribed doses. As shown in Figure 2, the most 
common reasons for missing doses were forgetting and being away 
from home. 
Figure 2: Reasons for missing doses (n = 180)
In the bivariate analysis, the only facilitator or factor that was 
significantly associated with ≥ 95% self-reported adherence was eating 
well (80.6% vs 64.5%; p = 0.025), whereas barriers or factors more 
likely and significantly associated with < 95% adherence included 
having used non-prescribed medicines (15.6% vs 3.9%; p = 0.008), 
having suffered from headaches (28.6 vs 14.6%; p = 0.03), and 
reported symptoms such as insomnia (27.3% vs 12.6%; p = 0.013) and 
abdominal pain (20.8% vs 9.7%; p = 0.037). 
In the multivariate analysis, the facilitators or factors that were 
significantly associated with a self- reported adherence level of ≥ 
95% were having initial bodyweight of less than 50 kg (p = 0.026) and 
viral load of > 33 000 copies/ml (p = 0.047). Other factors that were 
more likely but not significantly associated with ≥ 95% adherence 
included having a tertiary education and good working relationship with 
clinic staff, being employed and receiving a disability grant. Barriers 
or factors that were likely and significantly associated with less than 
optimal self-reported adherence were having used non-prescribed 
medicines (p = 0.01) and having reported insomnia (p = 0.01). 
Discussion
Overall only 57.2% reported taking ≥ 95% of their prescribed doses, 
while the mean number of doses missed was 2.7 (±3.9). In previous 
South African studies, the level of adherence reported by other 
investigators was higher than in this study.7,9 The level of self-reported 
adherence found in our study is a cause for concern because it 
points out to a possible threat of antiretroviral drug resistance.10 It 
is established that drug resistance strives well when HIV replication 
is incompletely suppressed and may reach as high as 50% against 
non-reverse transcriptase inhibitors.11 The implication of this finding 
is that the necessary investment to ensure an effective scale-up of 
ART must be made available in terms of human resources, finances, 
procedures and policies, buy-in from communities and public health 
interventions.12,13 
The use of non-prescribed medicines was significantly associated 
with a self-reported adherence level of less than 95% in the bivariate 
and multivariate analysis. This finding suggests that when patients 
have obtained medicines by their own initiative from other sources, 
they value them more and most probably take them while neglecting 
what was prescribed for them.14 The implication of this is that clinicians 
should regularly find out from patients whether they are taking any non-
prescribed medicines.
The majority of respondents reported at least one side or adverse 
effect. Self-reported adverse effects such as insomnia were 
significantly associated with an adherence level of less than 95% in 
the bivariate and multivariate analysis; while complaints of headaches 
and abdominal pain were significantly associated with a similar level 
of adherence in the bivariate analysis. This finding confirms what is 
well established from the literature, namely that side effects affect 
adherence negatively. Nevertheless, our findings differ from reports 
by Johnson and colleagues with regard to the types of side effects 
implicated. In this study it was insomnia, headaches and abdominal 
pain; while in theirs it was nausea, vomiting and skin rashes.15
With regard to reasons cited for missing doses, the findings from this 
study concur with reports from the literature that forgetting and being 
away from home were the most common.16 Limitations of this study 
included that causal relationships could not be determined due to the 
design of the study, and the fact the response rate was low, probably 
because of the fact that this was an exit interview – some interviewees 
just wanting to go back to their homes. 
In conclusion, self-reported barriers to optimal adherence included 
the use of non-prescribed drugs, and the presence of side effects 
such insomnia, headaches and abdominal pain, while eating well 
was a facilitator. These findings emphasised the need for better 
communication between patients and clinicians, and the need for 
integrating pharmacovigilance concepts in clinical practice.
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